Correction: ¹⁸ F-fluoroestradiol PET/CT measurement of estrogen receptor suppression during a phase I trial of the novel estrogen receptor-targeted therapeutic GDC-0810: Using an imaging biomarker to guide drug dosage in subsequent trials(Clin Cancer Res. (2017) 3:12 (3053-3060) DOI: 10.1158/1078-0432.CCR-16-219)

Yingbing Wang, Karen L. Ayres, Debra A. Goldman, Maura N. Dickler, Aditya Bardia, Ingrid A. Mayer, Eric Winer, Jill Fredrickson, Carlos L. Arteaga, Jose Baselga, Henry C. Manning, Umar Mahmood, Gary A. Ulaner

Research output: Contribution to journal › Comment/debate › peer-review

1 Scopus citations

Fingerprint

Dive into the research topics of 'Correction: ¹⁸ F-fluoroestradiol PET/CT measurement of estrogen receptor suppression during a phase I trial of the novel estrogen receptor-targeted therapeutic GDC-0810: Using an imaging biomarker to guide drug dosage in subsequent trials(Clin Cancer Res. (2017) 3:12 (3053-3060) DOI: 10.1158/1078-0432.CCR-16-219)'. Together they form a unique fingerprint.

Fingerprint

Medicine & Life Sciences